The enzyme PCSK9 binds to the hepatic LDL receptor and targets it for a intracellular degradation, leading to decreased number of LDL receptor on cells and reduced removal of circulating LDL cholesterol.
LDL cholesterol.
The usefulness of circulating PCSK9 as a marker for risk of coronary heart disease in the general population remains unclear.
In this large prospective population study, serum levels of PCSK9 were modestly associated with increased risk of myocardial infarction in age-and sexadjusted analysis. However, after adjustment for LDL-C and other lipids, the strength of the association was largely attenuated.
Our findings suggest that serum levels of 
SUMMARY
The usefulness of circulating proprotein convertase subtilisin-kexin type 9 (PCSK9) as a risk marker of coronary heart disease in the general population remains unclear. In a nested case-control study in Norway, 1, 488 incident myocardial infarctions were registered during 11.3 years of follow-up and compared with 3,819 controls. Compared with participants in the lowest quartile of PCSK9, myocardial infarction risk was 47% higher in the highest quartile after adjustment for age and sex. After additional adjustment for low-density lipoprotein cholesterol, the association was strongly attenuated. Thus, circulating PCSK9 does not contribute useful information in the assessment of myocardial infarction risk in the general population beyond the information C o n t r o l s . Controls were selected from the underlying cohort using incidence density sampling, which is the recommended procedure for nested case-control studies (17) . Before control selection, we had no information to indicate whether a sufficient serum volume was available, and we oversampled the controls, but as a minimum, 2 controls with available serum were selected per MI case, matched by age at risk and sex. Use of age at risk as a time dimension allows a very precise adjustment for age and is recommended for epidemiological studies in which the outcome is strongly age-dependent, as is the case for MI (18) .
Among the 58,761 participants who were eligible for inclusion at baseline, 1,700 participants were diagnosed in hospital with a first incident MI during a mean follow-up of 11.3 years. A total of 1,587 of these patients had a stored serum volume that was sufficient for PCSK9 analysis. As controls, 3,959 participants with sufficient and available serum volume were matched to the cases by age at risk and by sex. Responses to questions related to smoking were categorized as current, previous, or never smoking.
Creatinine was measured by the Jaffe method, and the day-to-day coefficient of variation was 3.5%.
Nonfasting serum concentrations of total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides were measured in fresh serum samples at
Levanger Hospital using enzymatic colorimetric methods with reagents from Boehringer Mannheim on a Hitachi 911 Autoanalyzer (Roche Diagnostics, Indianapolis, Indiana). The day-to-day coefficients of variation were 1.3% to 1.9%, 2.4%, and 0.7% to 1.3%, respectively. LDL-C was calculated using Figure 1 . Among MI cases, the median PCSK9 concentration was 128 ng/ml (interquartile range: 76 to 182 ng/ml) compared to 121 ng/ml (interquartile range: 69 to 174 ng/ml) among controls (p < 0.001).
]). Participants with
The median value was higher in women than in men;
136 ng/ml versus 116 ng/ml (p < 0.001).
The baseline characteristics of participants within each PCSK9 quartile are shown in Table 1 
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Laugsand et al. Table 2) . We also expressed PCSK9 concentrations as restricted cubic splines, and found that the age-and sex-adjusted association of PCSK9 with MI risk displayed a nonlinear shape. Thus, there was a gradual increase in MI risk starting at approximately 100 to 175 ng/ml of PCSK9, followed by a leveling off ( Figure 1A) . After adjustment for established cardiovascular risk factors, the cubic spline analysis suggested that PCSK9 concentrations were not associated with increased MI risk ( Figure 1B) . Values are n (%) or odds ratio (95% confidence interval). *For tests of trend of the association, we assigned each participant the median PCSK9 level within his or her quartile, and treated these median values as a continuous variable in the logistic models. †1 SD ¼ 47 ng/ml. ‡Adjusted for age and sex. §Adjusted for age, sex, and LDL-C. kAdjusted for age, sex, LDL-C, HDL-C, and triglycerides. ¶Adjusted for age, sex, diabetes mellitus, LDL-C, BMI, smoking, systolic blood pressure, diastolic blood pressure, triglycerides, HDL-C, log-transformed creatinine, and log-transformed C-reactive protein.
D E C E M B E R
CI ¼ confidence interval; OR ¼ odds ratio; other abbreviation as in Table 1 .
Laugsand et al. Table 2 ). Adjustment for untransformed hsCRP and creatinine instead of the logtransformed variables showed similar results (data not shown). Adjustment for time between last meal and the venipuncture had virtually no effect on the results (data not shown).
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DISCUSSION
In this large prospective population study of individuals free of clinical CVD at baseline, serum levels of PCSK9 were positively but modestly associated with risk of MI in age-and sex-adjusted analysis.
However, after adjustment for established CVD risk factors, the strength of the association was strongly attenuated. Most of the attenuation could be attributed to LDL-C followed by serum triglycerides and HDL-C. Thus, our results suggest that the association of PCSK9 may reflect an effect involving the metabolism of lipids rather than being an independent risk factor for MI. Moreover, our results are consistent with the biological understanding of PCSK9 and of its effect on atherosclerosis being mainly mediated by changes in LDL-receptor function.
The association of PCSK9 with CVD risk has not been well-studied in population studies. A few relatively small studies from the general population have prospectively investigated circulating PCSK9 levels and risk of CVD, and the results have been conflicting (11) (12) (13) . In a nested case-control study from the Nurses' Health Study, including 358 women in each group, Ridker et al. (12) reported that PCSK9 levels were not associated with increased risk of CVD events during 17 years of follow-up. Similarly, Zhu et al. (13) found no evidence for a strong association between log-transformed serum PCSK9 and CVD events in 1,527 middle-aged men over a 7-year follow-up after adjustment for established cardiovascular risk factors lipids and coronary heart disease is firmly established, the association between lipids and ischemic stroke is not equally robust (21) . The stronger association observed in the study of Leander et al. (11) could therefore reflect lipid independent cardiometabolic (e.g., inflammation, apoptosis) effects of PCSK9 with a stronger impact on non-MI CVD (22) .
Strengths of the present study include the relatively large sample size and the selection of a minimum of 2 controls for each of the 1,488 MI cases, preserving two-thirds of the statistical power that would be achieved by using the whole cohort. Other strengths are the prospective recording of incident MIs, and that biases resulting from recall or selfselection are avoided. Also, the incidence density sampling secures unbiased OR estimates of the incidence rate ratios that would be calculated in the underlying cohort. Thus, this type of nested casecontrol study is prospective in design and considered to be equivalent to cohort studies in terms of validity (17) . Moreover, all MIs were verified in the hospitals, and the specificity of the diagnosis is likely to be very high (17 founding from use of statins should be limited in our study. PCSK9 has been reported to display considerable diurnal variation (25, 26) . In the HUNT study, all blood samples were drawn between 8:00 AM and 4 PM, but we had no exact information on time during the day the blood sampling was done. However, adjustment for time between last meal and blood sampling had no effect on the estimated results. Nevertheless, a standardized sampling at 1 time would have been the best, and this represent a limitation in our study. 
CONCLUSIONS
